Loading
Sung-Bae Kim is a leading Korean breast oncologist on the steering committees of the trastuzumab emtansine and deruxtecan trials.
Sung-Bae Kim is Professor of Medical Oncology at Asan Medical Center in Seoul, specialising in breast cancer. He is a leading Korean breast oncologist who sits on the steering committees of the trastuzumab emtansine and trastuzumab deruxtecan trials, and has been an investigator on many pivotal HER2-positive and triple-negative breast cancer studies, including EMILIA, the DESTINY-Breast trials and immunotherapy combinations. His publications include the DESTINY-Breast03 trial comparing trastuzumab deruxtecan with trastuzumab emtansine in HER2-positive metastatic breast cancer. He co-leads Korean breast cancer research networks, with interests in HER2-positive disease and antibody-drug conjugates.
| Title | Journal | Year |
|---|---|---|
| Trastuzumab deruxtecan versus trastuzumab emtansine for HER2-positive metastatic breast cancer (DESTINY-Breast03) | NEJM | 2022 |
| DESTINY-Breast04: trastuzumab deruxtecan works in HER2-low breast cancer, creating a new treatable group | New England Journal of Medicine | 2022 |
For HER2-positive metastatic breast cancer that has progressed after trastuzumab and a taxane, trastuzumab deruxtecan is now the standard second-line treatment and T-DM1 has moved later in the sequence. The benefit is large enough that ADC design, not just the target, is understood to be what matters. Patients need lung monitoring because of the risk of pneumonitis.
Patients whose breast cancer was previously called HER2-negative may now be eligible for an effective HER2-directed drug if their tumour has even low-level HER2 staining, so pathology reports must now distinguish HER2-low (1+ or 2+/ISH-negative) from HER2-zero. This applies to metastatic disease after at least one line of chemotherapy; it does not mean these patients benefit from trastuzumab or other older HER2 drugs.
TILs are prognostic without chemotherapy, which is what a de-escalation biomarker has to show before trials omit treatment on its basis.
LOTUS and PAKT together made the PI3K/AKT/PTEN-altered subgroup the target population for AKT inhibitors in TNBC; the phase 3 IPATunity130 later failed to confirm it, which is why no AKT inhibitor is approved here.
Shares DESTINY-Breast03, DESTINY-Breast03: trastuzumab deruxtecan beats T-DM1 as second-line treatment of HER2-positive metastatic breast cancer, Trastuzumab emtansine, Trastuzumab deruxtecan.
Shares DESTINY-Breast03, DESTINY-Breast03: trastuzumab deruxtecan beats T-DM1 as second-line treatment of HER2-positive metastatic breast cancer, Trastuzumab emtansine, Trastuzumab deruxtecan.
Shares DESTINY-Breast03: trastuzumab deruxtecan beats T-DM1 as second-line treatment of HER2-positive metastatic breast cancer, DESTINY-Breast04: trastuzumab deruxtecan works in HER2-low breast cancer, creating a new treatable group, Trastuzumab deruxtecan, HER2.
Shares DESTINY-Breast04: trastuzumab deruxtecan works in HER2-low breast cancer, creating a new treatable group, Trastuzumab deruxtecan, HER2, HER2-positive breast cancer.
Shares DESTINY-Breast03, DESTINY-Breast03: trastuzumab deruxtecan beats T-DM1 as second-line treatment of HER2-positive metastatic breast cancer, Trastuzumab emtansine, Trastuzumab deruxtecan.
Shares DESTINY-Breast03: trastuzumab deruxtecan beats T-DM1 as second-line treatment of HER2-positive metastatic breast cancer, DESTINY-Breast04: trastuzumab deruxtecan works in HER2-low breast cancer, creating a new treatable group, HER2, HER2-positive breast cancer.
Shares Prognostic value of tumor-infiltrating lymphocytes in patients with early-stage triple-negative breast cancers (TNBC) who did not receive adjuvant chemotherapy, DESTINY-Breast03: trastuzumab deruxtecan beats T-DM1 as second-line treatment of HER2-positive metastatic breast cancer, Trastuzumab deruxtecan, HER2.
Shares DESTINY-Breast04: trastuzumab deruxtecan works in HER2-low breast cancer, creating a new treatable group, Trastuzumab deruxtecan, HER2, HER2-positive breast cancer.